Thursday, September 29, 2022


Biotechnology News Magazine

James Brady Joins Verona Pharma as Non-Executive Director

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

James Brady has joined the Verona Pharma plc board as a Non-Executive Director.

James Brady has extensive experience in the biopharmaceutical industry, serving in multiple leadership roles of increasing responsibility across the US, Europe, and China, during his 30-plus-year career at AstraZeneca.

He held national, regional, and global finance roles spanning corporate operations, manufacturing, commercial, marketing, market access, audit, international business, and biologics discovery and development. Most recently, James Brady served as Chief Financial Officer of MedImmune, the biologics discovery and development division of AstraZeneca. During his tenure at MedImmune, biologics grew to represent more than half of the product development portfolio of AstraZeneca and five biologics were successfully brought to market.

“We are delighted to welcome James to the Board,” said Dr. David Ebsworth, Chairperson of Verona Pharma. “He brings a wealth of leadership, strategic and commercial expertise, which will be key as we prepare to submit our New Drug Application for ensifentrine and progress our commercialization plans.”

Throughout his career at AstraZeneca, James had P&L and management responsibilities for significant operating units and finance functions and in addition served as the Chief Audit Executive for the Company. His experience spans the full product development cycle from early research and clinical development to sales and product contracting. Mr. Brady currently serves as a Non-Executive Director on the board of Panavance Therapeutics. He is a CPA, holds an MBA from Drexel University and a BS in accounting from St. Joseph University.

Verona Pharma also announces today that Dr. Andrew Sinclair, Ph.D., Partner and Portfolio Manager at Abingworth, will step down from the board as a Non-Executive Director at the conclusion of Verona Pharma’s Annual General Meeting on April 27, 2022.

Dr. Ebsworth added: “We would like to thank Andrew for his many contributions to Verona Pharma’s development over the past five years, including helping to progress our novel product candidate, ensifentrine, into Phase 3 clinical trials and complete a $200 million financing.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine